Last reviewed · How we verify
Weekly cisplatin with RT
Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription.
Cisplatin works by crosslinking DNA, thereby inhibiting DNA replication and transcription. Used for Non-small cell lung cancer, Ovarian cancer, Testicular cancer.
At a glance
| Generic name | Weekly cisplatin with RT |
|---|---|
| Also known as | Cisplatin |
| Sponsor | Korea Cancer Center Hospital |
| Drug class | Platinum-based chemotherapy |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This leads to cell death, particularly in rapidly dividing cancer cells. Cisplatin also induces apoptosis and can cause DNA damage, further contributing to its anticancer effects.
Approved indications
- Non-small cell lung cancer
- Ovarian cancer
- Testicular cancer
- Bladder cancer
- Stomach cancer
- Head and neck cancer
Common side effects
- Nausea and vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
- Kidney damage
- Hearing loss
- Tinnitus
- Peripheral neuropathy
Key clinical trials
- Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer (PHASE3)
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial (PHASE2)
- Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer (PHASE1)
- Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer (PHASE2)
- De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer (PHASE2, PHASE3)
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer (PHASE3)
- Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer (PHASE3)
- Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |